Abstract
Identification of amyloidosis on a prostate biopsy specimen raises suspicion for systemic amyloidosis. For patients at risk of prostate adenocarcinoma, a transrectal MRI ultrasound fusion (MRI-TRUS) guided biopsy of the prostate is often needed for further investigation. Our patient is a 70 year old male presenting from his primary care provider with an elevated PSA. The patient underwent MRI-TRUS fusion biopsy of the prostate, which demonstrated AL (lambda)-type amyloidosis, confirmed by mass spectrometry in addition to prostatic adenocarcinoma. He was subsequently diagnosed with primary amyloidosis of the prostate without evidence of other amyloid deposition sites.